



CORRECTION

Correction to: A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance

Ganesh Kumar Vemula · Pavan Badale · Petros Mavrogenis ·
Isabelle Lalande-Luesink · Michal Borkowski · David John Lewis

Published online: December 21, 2023
© Springer Healthcare Ltd., part of Springer Nature 2023

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-023-02699-4>

In this article Mnv Prasad Gajula was incorrectly denoted as being one of the equally contributing authors.

The correct ‘Author Contribution’ text is “Ganesh Kumar Vemula, Pavan Badale, Petros Mavrogenis, Isabelle Lalande-Luesink, Michal Borkowski and David J. Lewis has access to study data. All authors made important contributions to data acquisition, analysis, and/or interpretation of data. All authors reviewed manuscript drafts and have reviewed and approved the final version for submission.”

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-

NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s12325-023-02699-4>.

G. K. Vemula (✉) · P. Badale
Patient Safety and Pharmacovigilance,
Development, Novartis Pharma AG, Hyderabad,
India
e-mail: ganesh_kumar.vemula@novartis.com

P. Mavrogenis · I. Lalande-Luesink · M. Borkowski ·
D. J. Lewis
Patient Safety and Pharmacovigilance,
Development, Novartis Pharma AG, Basel,
Switzerland